ArticleEuropean journal of medical research2025
Association between the atherogenic index of plasma and major adverse cardiovascular events in patients with premature coronary artery disease.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Associations of the atherogenic index of plasma and its modified indices with the incidence and progression of cardiometabolic multimorbidity in individuals with cardiovascular-kidney-metabolic syndrome stages 0-3: a prospective cohort study.Cardiovascular diabetology · 2026Article
- The atherogenic index of plasma is associated with subclinical cardiac systolic dysfunction among obese patients: a cross-sectional study.Frontiers in nutrition · 2026Article
- Metabolic, Atherogenic, and Anthropometric Markers for Discrimination of Premature Coronary Artery Disease in a Predominantly Statin-Treated Cohort.Vascular health and risk management · 2026Observational
- Prognostic value of four insulin resistance indices in predicting new-onset hypertension: a retrospective cohort study.Frontiers in endocrinology · 2026Article
- Association of the atherogenic index of plasma with in-hospital mortality in patients with sepsis-induced coagulopathy.Lipids in health and disease · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe atherogenic index of plasma (AIP) as a novel lipid biomarker has been shown to be an important predictor of atherosclerosis and coronary artery disease. However, it remains unclear whether AIP has prognostic value for patients with premature coronary artery disease (PCAD). Therefore, the present investigation aims to explore the relationship between AIP and major adverse cardiovascular events (MACE) in the PCAD population.
methodsA total of 721 patients with PCAD diagnosed by coronary angiography were enrolled in this study. Their AIP was calculated as log [triglyceride (TG)/high-density lipoprotein-cholesterol (HDL-C)]. The primary outcome of this study was MACE, defined as a combination of cardiovascular (CV) death, coronary artery revascularization, non-fatal myocardial infarction (MI), and non-fatal stroke.
resultsAfter a median follow-up time of 52 months, 138 patients developed MACE. The patients in the highest AIP tertile group have a higher incidence of MACE (26.6% vs 11.8% and 19.8%, p < 0.001). The Kaplan-Meier curves demonstrated that there were significant differences in the risk of MACE among different AIP groups (log-rank p < 0.001). In addition, the multivariable Cox regression model showed that the hazard ratio of MACE in the highest tertile group was 2.27 (95% CI 1.30-3.94), and 1.33 (95% CI 1.06-1.67) for per SD increase in AIP.
conclusionsAIP is significantly associated with the risk of MACE in patients with PCAD and serves as a novel independent prognostic marker for this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.